NDAORALTABLET
Approved
Sep 2022
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Mechanism of Action
Tyrosine Kinase 2 Inhibitors
Pharmacologic Class:
Tyrosine Kinase 2 Inhibitor
Clinical Trials (5)
A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132
Started Feb 2026
35 enrolled
Systemic Lupus Erythematosus (SLE)Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
Started Dec 2025
366 enrolled
Plaque Psoriasis
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
Started Sep 2025
3,040 enrolled
Plaque Psoriasis
Deucravacitinib for Patients With Moderate/Severe Psoriasis: A Real-Life Experience in Italy
Started Aug 2025
200 enrolled
Psoriasis
A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis
Started Jul 2025
606 enrolled
Plaque Psoriasis
Loss of Exclusivity
LOE Date
Feb 11, 2043
206 months away
Patent Expiry
Feb 11, 2043
Exclusivity Expiry
Sep 9, 2027